alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 89, Number 183 (Friday, September 20, 2024)]
[Notices]
[Pages 77133-77134]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-21478]


-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project No. 2347-000]


Notice of Authorization for Continued Project Operation; Midwest 
Hydro, LLC

    The license for the Janesville Central Hydroelectric Project No. 
2347 was issued for a period ending August 31, 2024.
    Section 15(a)(1) of the FPA, 16 U.S.C. 808(a)(1), requires the 
Commission, at the expiration of a license term, to issue from year-to-
year an annual license to the then licensee(s) under the terms and 
conditions of the prior license until a new license is issued, or the 
project is otherwise disposed of as provided in section 15 or any other 
applicable section of the FPA. If the project's prior license waived 
the applicability of section 15 of the FPA, then, based on section 9(b) 
of the Administrative Procedure Act, 5 U.S.C. 558(c), and as set forth 
at 18 CFR 16.21(a), if the licensee of such project has filed an 
application for a subsequent license, the licensee may continue to 
operate the project in accordance with the terms and conditions of the 
license after the minor or minor part license expires, until the 
Commission acts on its application. If the licensee of such a project 
has not filed an application for a subsequent license, then it may be 
required, pursuant to 18 CFR 16.21(b),

[[Page 77134]]

to continue project operations until the Commission issues someone else 
a license for the project or otherwise orders disposition of the 
project.
    If the project is subject to section 15 of the FPA, notice is 
hereby given that an annual license for Project No. 2347 is issued to 
Midwest Hydro, LLC for a period effective September 1, 2024, through 
August 31, 2025, or until the issuance of a new license for the project 
or other disposition under the FPA, whichever comes first.
    If issuance of a new license (or other disposition) does not take 
place on or before August 31, 2025, notice is hereby given that, 
pursuant to 18 CFR 16.18(c), an annual license under section 15(a)(1) 
of the FPA is renewed automatically without further order or notice by 
the Commission, unless the Commission orders otherwise.
    If the project is not subject to section 15 of the FPA, notice is 
hereby given that Midwest Hydro, LLC is authorized to continue 
operation of the Janesville Central Hydroelectric Project under the 
terms and conditions of the prior license until the issuance of a 
subsequent license for the project or other disposition under the FPA, 
whichever comes first.

    Dated: September 13, 2024.
Debbie-Anne A. Reese,
Acting Secretary.
[FR Doc. 2024-21478 Filed 9-19-24; 8:45 am]
BILLING CODE 6717-01-P
----

----

----

----

----

----

----

----

----

----

----

|   |
|--------|

----

----

----

----

----

----

----

----

| ($ in millions)                                          | Q3-’10 | Q4-’10 | Q1-’11 | Q2-’11 | Q3-’11 | Q4-’11 |
|----------------------------------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|
| 1. Beginning Balance NPAs & 90+ Days Delinquent | $ 146.5      | $ 130.8      | $ 120.0      | $ 107.6      | $ 109.5      | $ 106.7      |
|  Non-Accrual                                        |         |         |         |         |         |         |
| 2. Add: New Non-Accruals                            |  15.5   |  27.4   |  11.7   |  26.7   |  21.4   |  10.2   |
| 3. Less: To Accrual/Payoff/Restructured             | ( 18.6)      | ( 14.5)      | ( 3.2)       | ( 8.3)       | ( 8.7)       | ( 7.6)       |
| 4. Less: To OREO                                    | ( 6.7)       | ( 7.0)       | ( 2.0)       | ( 1.6)       | ( 9.7)       | ( 1.2)       |
| 5. Less: Charge-offs                                | ( 11.8)      | ( 13.9)      | ( 9.4)       | (16.9)       | (11.6)       | (10.7)       |
| 6. Increase /(Decrease): Non-Accrual Loans     | (21.6)       | (8.0)        |  ( 2.9) |  ( .1)  |  (8.6)  |  (9.3)  |
|  Other Real Estate Owned (ORE)                      |         |         |         |         |         |         |
| 7. Add: New ORE Properties                          |  6.6    |  7.2    | 2.2          | 1.6          | 9.7          | 1.2          |
| 8. Less: ORE Sold                                   | (3.8)        | (4.2)        | ( 3.6)       | ( 1.6)       | ( 5.0)       | ( 3.3)       |
| 9. Less: ORE Losses (write-downs)                   | ( 1.4)       | ( 3.6)       | ( 2.5)       | ( 1.6)       | ( 0.7)       | ( 1.1)       |
| 10.  Increase /(Decrease): ORE                 | 1.4          | ( .6)        |  ( 3.9) |  ( 1.6) |  4.0    | (3.2)        |
| 11.  Increase /(Decrease): 90 Days Delinquent  | .8           | ( 4.0)       |  ( 0.6) |  ( 0.5) |  1.4    |  (1.0)  |
| 12. Increase /(Decrease): Restructured Loans        |  3.7    |  1.8    |  ( 5.0) |  4.1    | .4           | 7.6          |
| 13. Total NPA Change                                | (15.7)       | (10.8)       | (12.4)       |  1.9    |  (2.8)  |  (5.9)  |
| 14. Ending Balance NPAs & 90+ Days Delinquent   | $ 130.8      | $ 120.0      | $ 107.6      | $ 109.5      | $ 106.7      | $ 100.8      |

----

----

----

----

----

----
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[S. 2697 Introduced in Senate (IS)]

<DOC>

115th CONGRESS
  2d Session
                                S. 2697

   To require the awareness campaign regarding the risk of abuse of 
   prescription opioids if such drugs are not taken as prescribed to 
             include information about dispensing options.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                             April 18, 2018

Ms. Warren (for herself and Mrs. Capito) introduced the following bill; 
     which was read twice and referred to the Committee on Health, 
                     Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL

 
   To require the awareness campaign regarding the risk of abuse of 
   prescription opioids if such drugs are not taken as prescribed to 
             include information about dispensing options.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Unused Medications Awareness Act''.

SEC. 2. AWARENESS CAMPAIGNS.

    Section 102(b) of the Comprehensive Addiction and Recovery Act of 
2016 (Public Law 114-198) is amended--
            (1) in paragraph (2), by striking ``; and'' and inserting 
        ``;'';
            (2) in paragraph (3), by striking the period and inserting 
        ``; and''; and
            (3) by adding at the end the following:
            ``(4) dispensing options under section 309(f) of the 
        Controlled Substances Act, as applicable.''.
                                 <all>
```
<PAGE>   1
                                                                     EXHIBIT 3.6

AMENDMENT OF BYLAWS

     WHEREAS, this Board of Directors deems it to be in the best interests of
this Corporation to amend the Bylaws of this Corporation to decrease the number
of directors of this Corporation from six to five;

     NOW, THEREFORE, BE IT RESOLVED, that the last sentence of Section 2 of
Article III of the Bylaws be amended, effective as of March 15, 2000, to read
in full as follows: "The exact number of directors shall be five until changed
as provided in this Section 2."

     RESOLVED FURTHER, that the Secretary of this Corporation is authorized and
directed to execute a certificate of the adoption of said amendment to the
Bylaws and to enter said amendment as so certified in the minute book of this
Corporation.
# C_2022089EN.01000101.xml

| 25.2.2022 | EN | Official Journal of the European Union | C 89/1 |
| --- | --- | --- | --- |

25.2.2022

EN

Official Journal of the European Union

C 89/1

---

Non-opposition to a notified concentration

(Case M.10577 – FSN CAPITAL VI / OPTIGROUP / HYGAS / BFG / TPC)

(Text with EEA relevance)

(2022/C 89/01)

On 17 February 2022, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32022M10577. EUR-Lex is the online point of access to European Union law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32022M10577. EUR-Lex is the online point of access to European Union law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---
Exhibit 4.01














---
EXHIBIT 32.2

Certification of Chief Financial Officer

Pursuant to 18 U.S.C. § 1350, as created by
Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of SCPIE Holdings Inc. (the Company) hereby certifies, to such officers knowledge, that:

(i) the accompanying Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2006 (the
Report) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.



|                        |  |  |  |                        
|----------------------- |  |  |  | -----------------------
|                        |  | 
|Dated: November 7, 2006 |  |  |  | /s/ Robert B. Tschudy  
|                        |  |  |  | Robert B. Tschudy      
|                        |  |  |  | Chief Financial Officer

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350,
and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any
general incorporation language in such filing.
IN THE SUPREME COURT OF PENNSYLVANIA

MIDDLE DISTRICT

COMMONWEALTH OF PENNSYLVANIA,

Respondent

v.

MONICA ANNE MARIE MATULA,

Petitioner

:

:

:

:

:

:

:

:

:

:

:

No. 543 MAL 2018

Petition for Allowance of Appeal from 

the Order of the Superior Court

ORDER

PER CURIAM

AND NOW, this 4th day of February, 2019, the Petition for Allowance of Appeal is 

DENIED.
# C_2022180EN.01001401.xml

| 3.5.2022 | EN | Official Journal of the European Union | C 180/14 |
| --- | --- | --- | --- |

3.5.2022

EN

Official Journal of the European Union

C 180/14

---

Prior notification of a concentration

(Case M.10629 – CSL / VIFOR PHARMA)

(Text with EEA relevance)

(2022/C 180/05)

1.

This notification concerns the following undertakings:

| — | CSL Behring AG (‘CSL Behring’, Australia), controlled by CSL Limited (‘CSL’, Australia), a public company listed on the Australian Security Exchange, |
| --- | --- |

—

CSL Behring AG (‘CSL Behring’, Australia), controlled by CSL Limited (‘CSL’, Australia), a public company listed on the Australian Security Exchange,

| — | Vifor Pharma Limited (‘Vifor Pharma’, Switzerland), a public company listed on the Swiss Stock Exchange. |
| --- | --- |

—

Vifor Pharma Limited (‘Vifor Pharma’, Switzerland), a public company listed on the Swiss Stock Exchange.

CSL will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control over Vifor Pharma.

The concentration is accomplished by way of public bid announced by CSL Limited on 14 December 2021.

2.

| — | CSL is a biotechnology company with a portfolio of medicines, including those that treat hemophilia and immune deficiencies (through CSL Behring), as well as vaccines to prevent influenza (through Seqirus), and through CSL Plasma, a division of CSL Behring, it operates a plasma collection network, |
| --- | --- |

—

CSL is a biotechnology company with a portfolio of medicines, including those that treat hemophilia and immune deficiencies (through CSL Behring), as well as vaccines to prevent influenza (through Seqirus), and through CSL Plasma, a division of CSL Behring, it operates a plasma collection network,

| — | Vifor Pharma is active worldwide in the development, manufacturing, and marketing of pharmaceutical products for the treatment of iron deficiency, nephrology (kidney care), and cardio-renal therapies. |
| --- | --- |

—

Vifor Pharma is active worldwide in the development, manufacturing, and marketing of pharmaceutical products for the treatment of iron deficiency, nephrology (kidney care), and cardio-renal therapies.

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10629 – CSL / VIFOR PHARMA

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

| European Commission |
| --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---
NOTICE OF PUBLIC COMMENT PERIOD

The West Virginia Department of Environmental Protection (DEP) is announcing an

opportunity for public comment on a proposed revision to the State Implementation Plan (SIP)

regarding the most recently promulgated National Ambient Air Quality Standards (NAAQS) for

ozone and fine particulate matter. The SIP is the plan developed by West Virginia in order to

fulfill its responsibilities under the Clean Air Act (CAA) to attain and maintain the NAAQS

promulgated by the U.S. Environmental Protection Agency (U.S. EPA). The public comment

period begins August 21, 2009 and ends September 21, 2009.

In this proposed revision to the SIP, West Virginia is demonstrating that it has adequate

resources and authority to implement the 2006 PM2.5 NAAQS and the 2008 8-hour ozone

NAAQS. Compliance with specific CAA section 110(a)(2) requirements is detailed in a

document demonstrating that the State meets these express requirements through authorities

granted under state laws and regulations, as well as implementation of existing air programs.

DEP is seeking comments on whether the document adequately demonstrates West Virginia’s

compliance with the pertinent federal CAA mandates related to these so-called infrastructure

elements. Additionally, the state is supplementing its existing Section 110(a)(2)(A)-(M)

infrastructure SIP for the 1997 PM2.5 and 8-hour ozone NAAQS, only with respect to the

enforcement authority requirements under CAA Section 110(a)(2)(C).

Upon completion of the public notice period, and after addressing any written comment,

the DEP will submit the final documentation to the U.S. EPA as a revision to the SIP. This

proposed SIP revision is considered to be non-controversial in nature. Therefore, a public

hearing will be held only if requested in writing, and the written request is received by

September 21, 2009. Any person who requests a public hearing should identify any substantive

issue they intend to raise in a hearing. If properly requested, the hearing will be held beginning at

6:00 p.m. on September 28, 2009 at the address below and the public comment period will be

extended until the close of the hearing. A public notice announcing whether a hearing will be

held will be posted in the West Virginia Register published on September 25, 2009. 

Copies of the proposed CAA §110(a)(2) SIP revision may be viewed between 8:30 a.m.

and 4:30 p.m. at the DEP-Division of Air Quality, 601 57th SE, Charleston, WV 25304,

beginning August 21, 2009, or electronically upon e-mail request to:

Tammy.L.Mowrer@wv.gov. The proposal may also be accessed via the following web address:

http://www.wvdep.org/item.cfm?ssid=8&ss1id=376.

Send written comments to be included in the formal record to John A. Benedict, Director,

Division of Air Quality at the above address. Please identify the document to which the

comments apply, the commenter’s name, address, and telephone number. Comments will also

be accepted by e-mail if received by 5:00 p.m. on September 21, 2009 to:

Tammy.L.Mowrer@wv.gov. Comments submitted by U.S. Mail must be postmarked by

September 21, 2009.
EXHIBIT 31.1**CERTIFICATION**I, Igor Gonda, certify that:1. I have reviewed this Quarterly Report on Form 10-Q of Aradigm Corporation;     2. Based on my knowledge, this report does not contain any untrue statement of a material factor omit to state a material fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading with respect to the periodcovered by this report;     3. Based on my knowledge, the financial statements, and other financial information includedin this report, fairly present in all material respects the financial condition, results ofoperations and cash flows of the registrant as of, and for, the periods presented in this report;     4. The registrant’s other certifying officer and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and15d-15(e)) for the registrant and have:     a) designed such disclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that material information relating tothe registrant, including its consolidated subsidiaries, is made known to us by others within thoseentities, particularly during the period in which this report is being prepared;     b) evaluated the effectiveness of the registrant’s disclosure controls and procedures andpresented in this report our conclusions about the effectiveness of the disclosure controls andprocedures, as of the end of the period covered by this report based on such evaluation; and     c) disclosed in this report any change in the registrant’s internal control over financialreporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourthfiscal quarter in the case of an annual report) that has materially affected, or is reasonablylikely to materially affect, the registrant’s internal control over financial reporting; and     5. The registrant’s other certifying officer and I have disclosed, based on our most recentevaluation, of internal control over financial reporting, to the registrant’s auditors and theaudit committee of the registrant’s board of directors (or persons performing the equivalentfunctions):     a) all significant deficiencies and material weaknesses in the design or operation of internalcontrol over financial reporting which are reasonably likely to adversely affect the registrant’sability to record, process, summarize and report financial information; and     b) any fraud, whether or not material, that involves management or other employees who have asignificant role in the registrant’s internal control over financial reporting.                                     /s/ Igor Gonda   Igor Gonda        *President and Chief Executive Officer*   Dated: August 14, 2007
Docket No: FAA-2014-1043 Dir ID: 2013-NM-079-AD
# Journal officiel C 303A/15 s

| | ISSN 1977-0936 |
| --- | --- |
| Journal officiel
  de l'Union européenne | C 303A |
| | |
| Édition de langue française | Communications et informations | 58e année15 septembre 2015 |

ISSN 1977-0936

Journal officiel

de l'Union européenne

C 303A

Édition de langue française

Communications et informations

58e année15 septembre 2015

---

| Numéro d'information | Sommaire | page |
| --- | --- | --- |
| | V   Avis |
| | PROCÉDURES ADMINISTRATIVES |
| | Office européen de sélection du personnel (EPSO) |
| 2015/C 303A/01 | Liste de réserve — Concours général — EPSO/AST-SC/02/14 — Agents de sécurité interne (SC 1) | 1 |

Numéro d'information

Sommaire

page

V   Avis

PROCÉDURES ADMINISTRATIVES

Office européen de sélection du personnel (EPSO)

2015/C 303A/01

Liste de réserve — Concours général — EPSO/AST-SC/02/14 — Agents de sécurité interne (SC 1)

1

---

| FR | |
| --- | --- |

FR

---

V Avis

PROCÉDURES ADMINISTRATIVES

Office européen de sélection du personnel (EPSO)

| 15.9.2015 | FR | Journal officiel de l'Union européenne | CA 303/1 |
| --- | --- | --- | --- |

15.9.2015

FR

Journal officiel de l'Union européenne

CA 303/1

---

Liste de réserve (1)

Concours général

EPSO/AST-SC/02/14 — Agents de sécurité interne (SC 1)

(2015/C 303 A/01)

| BACCOLINI | Riccardo Maria |
| --- | --- |
| BOGAERTS | Joachim |
| BOHY | Geert |
| BOTEA | Corina-Ionica |
| CORREIA NEVES CORDEIRO DE AZEVEDO | Rui |
| FERNANDEZ RAMOS | Pablo |
| ΙΟΑΝ | Aurelian Mihut |
| IVANOV | Catalin |
| JACOBS | Iris |
| MARINKOVIC | Vladimir |
| MATHIEU | Fabrice Amour Jenny |
| MURARU | Stefan Marian |
| NEGOITA | Adrian |
| NGELIAS | Nikolaos |
| NIEMINEN | Jörgen |
| PACHECO BERNARDINO | Sebastien |
| PACIFICO | Marco |
| PANS | Christophe |
| PAUSESCU | Alexandru |
| RUIZ LOZANO | Jose-Manuel |
| SARDELLI | Silvia |
| SCHNELL | Karine |
| STEFANAKAKIS | Constantin |
| STOIAN | Valeria |
| SZÉPLAKI | Florian |
| VERLEGH | Eric |
| VUKOSAV | Denis |
| ZIPIS | Emanuel |

BACCOLINI

Riccardo Maria

BOGAERTS

Joachim

BOHY

Geert

BOTEA

Corina-Ionica

CORREIA NEVES CORDEIRO DE AZEVEDO

Rui

FERNANDEZ RAMOS

Pablo

ΙΟΑΝ

Aurelian Mihut

IVANOV

Catalin

JACOBS

Iris

MARINKOVIC

Vladimir

MATHIEU

Fabrice Amour Jenny

MURARU

Stefan Marian

NEGOITA

Adrian

NGELIAS

Nikolaos

NIEMINEN

Jörgen

PACHECO BERNARDINO

Sebastien

PACIFICO

Marco

PANS

Christophe

PAUSESCU

Alexandru

RUIZ LOZANO

Jose-Manuel

SARDELLI

Silvia

SCHNELL

Karine

STEFANAKAKIS

Constantin

STOIAN

Valeria

SZÉPLAKI

Florian

VERLEGH

Eric

VUKOSAV

Denis

ZIPIS

Emanuel

La validité de cette liste expirera le 24 juillet 2018.

---

(1)  À la demande expresse d’un lauréat, son nom n’est pas publié.

---